



ISSN (E): 2277-7695
 ISSN (P): 2349-8242
 NAAS Rating: 5.23
 TPI 2023; 12(7): 3733-3742
 © 2023 TPI
www.thepharmajournal.com
 Received: 25-05-2023
 Accepted: 20-06-2023

Gayathri SL
 Ph.D. Research Scholar,
 LPM Division Artificial Breeding
 Research Centre, ICAR-National
 Dairy Research Institute,
 Karnal, Haryana, India

Bhakat M
 Principal Scientist, LPM
 Division Artificial Breeding
 Research Centre, ICAR-National
 Dairy Research Institute,
 Karnal, Haryana, India

Mohanty TK
 Principal Scientist, LPM
 Division Artificial Breeding
 Research Centre, ICAR-National
 Dairy Research Institute,
 Karnal, Haryana, India

Assessment of antibacterial efficacy of *Moringa oleifera* extracts -A comparative study on mastitic and non-mastitic cultures

Gayathri SL, Bhakat M and Mohanty TK

Abstract

The medicinal properties of *Moringa oleifera* are utilised worldwide, especially its antimicrobial activity, based on which several preparations are available in the market. The present study evaluates the antibacterial activity of aqueous extracts of moringa leaf, pods, gum powder, and seed oil against specific microbial cultures. Also, the zone of inhibition was compared among the mastitic and non-mastitic cultures against the different Moringa extracts. The microbial cultures were activated before the antimicrobial activity estimation. The results revealed that the mastitic cultures showed the highest zone of inhibition compared to the non-mastitic cultures for the different concentrations of *M. oleifera* aqueous leaf extracts, pods, and gum powder for different dilutions. The different bacterial cultures showed a significant increase ($p < 0.05$) in the mean values of the zone of inhibition of different concentrations of *M. oleifera*, and these cultures differed significantly ($p < 0.01$) within the MIC for various dilutions. For different strains of *E. coli* and *Staphylococcus aureus*, the mean values of the zone of inhibition ranged from 2-26 and 2-21.50mm for *M. oleifera* aqueous leaf extract, 9-25 and 8-27mm for *M. oleifera* seed oil extracts, 15-27 and 9-28mm for *M. oleifera* pods powder aqueous extract, 11-24 and 4-17mm for *M. oleifera* gum powder aqueous extract, respectively for various concentrations from 100-300 μ l. Mastitic cultures were more susceptible to *M. oleifera* extracts and reflected an increase in zone of inhibition with an increase in concentration (100-300 μ l) and dilution than the non-mastitic cultures. Thus, the present study reveals that the various extracts of *M. oleifera* could be used in the development of prophylactic herbal preparations against mastitis causative agents.

Keywords: *M. Oleifera* seed oil, *M. Oleifera* leaf, *M. Oleifera* pods, *M. Oleifera* gum, mastitis

Introduction

The miracle tree *Moringa oleifera* comes under the family Moringaceae and is distributed worldwide (Anwar *et al.*, 2007)^[7] with its vibrancy in the form of 33 species (Daba, 2016)^[14]. These highly adaptable plant varieties survive in varied climatic conditions (Anwar *et al.*, 2007)^[7]. Moringa is locally referred to as "Sajna"- "Muringa" (India), "Sohnjana" (Pakistan), and in some other countries as "Horse radish" and "Drumstick". Moringa, a perennial plant, can be harvested several times a year. Moringa has several medicinal properties, antioxidant activities (Anwar *et al.*, 2007)^[7], and nutritional advantages, and it is highly suggested to be incorporated into the human diet (Haldar and Kosankar, 2017)^[24]. It contains several good-quality proteins, vitamins, minerals, and fiber (Fuglie, 1999)^[17]. The superiority of Moringa in comparison to other sources is that it has ten times more vitamin A than carrots, 15 times more potassium than bananas (Saini *et al.*, 2016)^[53], 9 times more protein than yogurt, 25 times more iron than spinach, 7 times more vitamin C than oranges and 17 times more calcium than milk (Daba, 2016)^[14]. Leafy tips of *Moringa oleifera*, per 100 g, contain 78% water, 64 kcal energy, 9.4 g protein, 1.4 g fat, 8.3 g carbohydrates, and 2.0 g dietary fiber (Grubben and Denton, 2004)^[22]. Moringa's properties and contents can cure many deficiencies and diseases (Elgamily *et al.*, 2016)^[15]. Moringa leaves to aid in treating flu, heartburn, and hyperglycaemia and reduces cholesterol, asthma, diarrhoea, pneumonia, and blood pressure. The plant leaves manifest antimicrobial, anticancer, antioxidant, and antidiabetic properties (Onsare *et al.*, 2013)^[39]. Moringa seed powder exhibits its marked potency in treating rheumatism, hyperthyroidism, cramp, Crohn's disease, epilepsy, gout, and sexually transmitted infections, and contains anti-inflammatory, antimicrobial agents (Ighodaro and Akinloye, 2018)^[25]. Root bark exhibits anticancer, anti-inflammatory, and cardiac stimulant agents. Moringa flower has hypocholesterolemic and anti-arthritis properties that aid in the cure of diseases of the liver, diarrhoea, spleen problem, and joint pain (Anwar *et al.*, 2007)^[7]. *M.*

Corresponding Author:
Gayathri SL
 Ph.D. Research Scholar,
 LPM Division Artificial Breeding
 Research Centre, ICAR-National
 Dairy Research Institute,
 Karnal, Haryana, India

oleifera has coagulative properties that aid wastewater treatment (Abraham and Okon, 2014) [2]. The plant has a highly superior antimicrobial peptide/protein (4 - 50kDa) that induces a resistance mechanism (Raj *et al.*, 2011) [49] and plays a significant role in innate immune response (Golla *et al.*, 2006) [19]. These antimicrobial peptides/proteins are present in Moringa's flower, seed, leaves, stem, and roots of Moringa and play a vital role in defence against pathogenic parasites, fungi, viruses, bacteria, and neoplastic cells (Raj *et al.*, 2011) [49]. These peptides/ proteins inhibit the growth of fungi through molecular routes such as binding to the chitin or enhancing the permeability of the cell wall (Chuang *et al.*, 2007) [12]. Antimicrobial peptides interact with the membrane via cationic amino acids attracted to the phospholipid head, and hydrophobic anionic peptides interact with the aliphatic fatty acids (Zasloff, 2002; Koczulla and Bals, 2003) [68, 31]. Thus, membrane destabilization is created, and leakage of cytoplasmic contents, loss of membrane potential, change of membrane permeability, lipid distribution, the entry of the peptide and blocking of anionic cell components or the triggering of autolytic enzymes (Zasloff, 2002) [68] kills bacteria. Consequently, every part of the Moringa has an exceptional blend of activities that can utilize for herbal and pharmaceutical preparations.

Mastitis is a multi-etiological production disease that creates havoc regarding economic loss among dairy farmers across the globe. The major pathogens causing mastitis are *Staphylococcus aureus*, *Streptococcus uberis*, *E. coli*, *Streptococcus bovis*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, and *Klebsiella pneumonia*. The minor pathogens like *Proteus* spp., *Brucella abortus*, *Klebsiella oxytoca*, *Mycoplasma* spp., *Pseudomonas aeruginosa*, *Nocardia* spp., *Pasteurella* spp., *Protothecazopfii*, *Corynebacterium bovis*, *Protothecawickerhamii* and yeast (Calvinho and Tirante, 2005; Awale *et al.*, 2012) [11, 9] attributes to the transmission of mastitis from subclinical to next stage of mastitis. Among them, *S. aureus* is responsible for causing subclinical mastitis (SCM) (Sakwinska *et al.*, 2011) [54], accounting for 25.64 percent in specific mastitis, 12.24 percent in latent cases, and owing to its adaptational talent in surviving extreme environments (Sharma and Maiti, 2010) [57]. Throughout the world, several studies have been conducted regarding coagulase-negative *Staphylococci* (CNS), the most isolated pathogen from milk (Radostits *et al.*, 2006), and its prevalence rate is highest in crossbred milch cattle (Mir *et al.*, 2014) [36]. CNS is the rising mastitis pathogen, which belongs to normal skin microbiota. Pilipčincová *et al.* (2010) [44] reported that the CNS forms a protective biofilm, which enables them to linger on to the milking machine and the milker's hand, which in turn aids in the spread of infection. Unhygienic circumstances enhance the microbes' favourable condition to flare up as an opportunistic pathogen in the teat, causing mastitis. Another commonly encountered mastitic pathogen is *Corynebacteria* (Pitkala *et al.*, 2004) [45], which persists with routine teat dip usage but could be eliminated using dry cow antibiotic therapy. In New Zealand, the primary mastitis-causing organism is *Streptococcus uberis* (Zadoks *et al.*, 2011) [67]; in the Midwestern United States, it is coliforms (Zadoks and Fitzpatrick, 2009) [66] and in India, it is *Staphylococcus* sp., *Streptococcus* sp., and *E. coli* (Krishnamoorthy *et al.*, 2017) [32]. Scientific studies related to the comparison among the mastitic and non-mastitic cultures against various extracts of

different dilutions of *Moringa oleifera* are limited. Thus, the present study focuses on the assessment of the antibacterial efficacy of *Moringa oleifera* leaf aqueous extract, *Moringa oleifera* pods powder aqueous extract, *Moringa oleifera* seed oil extract, *Moringa oleifera* gum powder aqueous extract against different cultures of NCDC (non-mastitic) and Mastitis causative agents obtained from the National Referral Centre for milk quality and Safety lab cultures.

Materials and Methods

The *Moringa oleifera* was harvested from the Artificial Breeding Research Centre (ABRC) garden of ICAR- National Dairy Research Institute (NDRI), Karnal, Haryana. A single source of plant material was used throughout the experiment. The National Collection of Dairy Cultures (NCDC) cultures used were NCDC-208 (*Streptococcus agalactiae*), NCDC-138 (*Klebsiella pneumoniae*), NCDC-133 (*Staphylococcus aureus*), and NCDC-135 (*Escherichia coli*). The current study also used the National Referral Centre for milk quality and Safety (NRCMQS) cultures of *Escherichia coli* and *Staphylococcus aureus* organisms isolated from mastitis milk. The cultures were activated using brain heart infusion broth before the MIC estimation.

Preparation, standardization, and MIC estimation of:

a. *Moringa oleifera* leaf aqueous extract

The hot water *Moringa oleifera* leaf aqueous (MOLA) extract was prepared according to the procedure developed at ABRC, ICAR-NDRI, Karnal, Haryana. *Moringa oleifera* trees within the ABRC garden were identified, and mature fresh leaves were harvested. The leaves were weighed, washed with fresh water, and then air-dried for 24 hours at room temperature. The dried leaves were kept in a hot-air oven at 45°C to remove moisture. After drying, moisture loss was determined before blending and storing at 4°C. The whole experiment was conducted using a single source of dried leaf powder. For MOLA extract preparation, fifty grams of dried *Moringa oleifera* leaf powder was soaked in 250ml of autoclaved distilled water (1:5 ratio) and incubated at 55 °C overnight in a hot air oven. After incubation, filtrate and leaf residue was separated using cheesecloth. Further, the filtrate was filtered using HiMedia® paper grade-40 filter paper, and till further use, the aqueous extract was aliquoted and stored at -20 °C. Further, the obtained *Moringa oleifera* leaf aqueous extract was standardized, and the efficacy was analyzed on selected bacterial cultures. The antimicrobial activity of the *Moringa oleifera* leaf aqueous extract against the selected non-mastitic cultures obtained from NCDC and mastitis organisms isolated during the previous experiments from milk obtained from NRCMQS was performed according to the method standardized by Wang *et al.* (2012) [64]. The plates containing 15ml nutrient agar medium were poured into Petri plates. The culture was activated before the start of the experiment. Soft agar containing 10⁵ target cultures was overlaid. The wells were made with the help of a well borer. After that, MOLA extract was added at different selected concentrations to other wells. The plates were kept aside for proper diffusion. Bacterial plates were incubated at 37 °C for 24 hours. The MIC formed was measured in mm at the end of the experiment. The obtained data were further processed and analyzed using suitable statistical software.

b. *Moringa oleifera* seed oil (MOSO) preparation: The

MOSO was prepared based on the procedure developed by Saad (2015)^[52]. *Moringa oleifera* pods were plucked from the ABRC garden and cleaned. The pods were sun-dried, and the seeds were removed using a knife manually. The seeds thus obtained were cleaned thoroughly. After cleaning, the seeds were put inside the electric oven to reduce the moisture content further. Then, the seeds were undergone size reduction by grinding using a domestic blender. The ground seeds were sieved using a 250µm sieve and weighed using an electronic balance. Oil extraction was carried out using the Soxhlet apparatus with n-hexane as solvent. 20g of the ground sample was poured into the thimble. Two third volume of the round bottom flask was filled with the solvent. The heating mantle was adjusted to about (60- 70) °C, and heating commenced. As the solvent was heated continuously, it evaporated and condensed back into the sample in the thimble. The oil extracted, containing some portion of the solvent, was then recycled back to the round bottom flask as it refluxed. The total reflux process continued until complete oil extraction was observed. A rotary evaporator was used to separate the oil from the solvent at the temperature of 65°C. The obtained oil was stored at room temperature for further use. The MIC estimation was carried out similarly to the MOLA extract.

c. *Moringa oleifera* pod powder aqueous (MOPPA) extract:

The preparation of *Moringa oleifera* pods was carried out based on the procedure developed by Gull *et al.* (2016). *Moringa oleifera* pods were plucked from the ABRC garden and cleaned. The pods (500g) were thoroughly air-dried and pulverized mechanically into powder using an electric grinder. The powder (20g) was extracted by soaking in 100mL of distilled water in screw-capped 250mL conical flasks for 24 hours with shaking at 160rpm in an orbital shaker at ambient temperature. The extracts were filtered through eight layers of muslin cloth, and then the filtrate was subjected to filtration through filter paper grade 40. The aqueous extract was aliquoted and stored at -20 °C till further use. The standardization and MIC estimation were carried out similarly to the MOLA extract.

d. *Moringa oleifera* gum powder aqueous (MOGPA) extract

The preparation for *Moringa oleifera* gum was carried out based on the procedure developed by Panda *et al.* (2006)^[41]. The gum was collected from the trees (injured site) of the ABRC garden. It was dried, ground, and passed through sieve no 80. Dried gum (10g) was stirred in distilled water (250 ml) for 6-8h at room temperature. The supernatant was obtained by centrifugation. The residue was washed with water, and the washings were added to the separated supernatant. The procedure was repeated four more times. Finally, the supernatant was made up to 500ml and treated with twice the volume of acetone by continuous stirring. The precipitated material was washed with distilled water and dried at 50-60° under a vacuum. 20g of MOGP- precipitated material was added to 100 ml distilled water in a conical flask and incubated in an orbital shaker for 24 hours at 55 °C. The obtained extract was filtered by using a Watman filter paper

grade 42. The aqueous extract was aliquoted and stored at -20 °C till further use. The standardization and MIC estimation were carried out similarly to the MOLA extract.

Statistical analysis

The data was analyzed using SPSS 26.0 software (IBM Corporation, Armonk, New York, USA). One-way ANOVA was used to estimate the antibacterial activity level of different extracts concentrations against the selected cultures with a significance level of $p < 0.01$. The post hoc used was Duncan's multiple range test. A univariate linear model was used to estimate the significance level at $p < 0.05$ of different extract concentrations in each culture under consideration.

Results

a. *Moringa oleifera* leaf aqueous extract

The *Moringa oleifera* leaf aqueous extract (hot) was prepared according to the standard procedure. Two sets of dilutions, *i.e.*, 1:4 (1g MOL powder in 4ml hot water) and 1:5 (1g MOL powder in 5ml hot water) of different concentrations (50, 100, 150, 200, 250µl) were used against the selected organisms to find out the MIC of hot water extract prepared. The control used was 50 µl of antibiotic (oxytetracycline). The MIC was calculated according to standard procedure and is depicted in Table 1 for 1:5 and Table 2 for 1:4 dilutions.

MIC estimation of MOLAE for 1:5 dilution

The values of MIC (zone of inhibition-2mm) were comparable among the different concentrations of MOLAE and were significant ($p < 0.05$) to control (OTC) (zone of inhibition-32mm) for NCDC 208. For NCDC 135, 133, and 138, the mean values of the zone of inhibition showed a significant increase ($p < 0.05$) as the concentration of MOLAE increased from 50- 250µl. A similar increase was observed for NRCMQS cultures also. For 50µl concentration of MOLAE, NRCMQS *S. aureus* showed the highest mean value of zone of inhibition (9.50m). But, for 100 µl concentration of MOLAE, NRCMQS *E. coli* showed the highest mean value of zone of inhibition of 16.00mm. The highest mean values zone of inhibition for 150, 200, and 250 µl concentrations of MOLAE were observed in NCDC 135 with values of 21.00mm, 22.00mm, and 24.00mm, respectively. Thus, all the cultures showed a significant increase in MIC values of different concentrations of MOLAE to the control ($p < 0.05$), and other cultures differ significantly within the concentrations of MOLAE ($p < 0.01$).

MIC estimation of MOLAE for 1:4 dilution

The values of MIC among NCDC 135, 133, 138, and NRCMQS *E. coli* and *S. aureus* showed a significant increase ($p < 0.05$) as the concentration increased from 50- 100 µl. Within a concentration, different cultures varied significantly in the mean values of the zone of inhibition ($p < 0.01$). The highest mean values of the zone of inhibition for 50, 100, 150, 200, and 250 µl concentration was observed in NCDC 138 (12.00mm), NRCMQS *S. aureus* (17.50mm), NCDC 138 (20.00mm), NCDC 138 (21.00mm) and NCDC 138 (27.00mm), respectively. All values of MIC showed a significant difference compared to the control group of MOLAE (Table 2).

Table 1: Mean \pm S. E. of MIC of different concentrations of MOLAE (hot water) at 1:5 dilution against the selected microorganism

Zone of inhibition (mm)	Concentrations of MOLAE (hot water) -MIC (μ l) for 1:5 dilution					
	Microorganisms	50	100	150	200	250
NCDC 208	2.00 ^{Ap} \pm 0.07	2.00 ^{Ap} \pm 0.06	2.00 ^{Ap} \pm 0.07	2.00 ^{Ap} \pm 0.05	2.00 ^{Ap} \pm 0.07	32.00 ^{Dq} \pm 0.51
NCDC 135	2.00 ^{Ap} \pm 0.06	11.00 ^{Cq} \pm 0.17	21.00 ^{Er} \pm 0.16	22.00 ^{Fs} \pm 0.14	24.00 ^{Fi} \pm 0.26	29.04 ^{Au} \pm 0.67
NCDC133	2.00 ^{Ap} \pm 0.08	10.00 ^{Bq} \pm 0.09	13.00 ^{Br} \pm 0.18	13.50 ^{Bs} \pm 0.16	14.00 ^{Bt} \pm 0.27	32.06 ^{Du} \pm 0.55
NCDC 138	2.00 ^{Ap} \pm 0.07	16.00 ^{Eq} \pm 0.16	19.00 ^{Dr} \pm 0.13	21.00 ^{Es} \pm 0.29	23.00 ^{Et} \pm 0.14	31.00 ^{Cu} \pm 0.68
NRCMQS <i>E. coli</i>	8.00 ^{Bp} \pm 0.15	16.00 ^{Fq} \pm 0.13	18.00 ^{Dr} \pm 0.18	20.00 ^{Ds} \pm 0.15	21.00 ^{Dt} \pm 0.11	30.50 ^{BCu} \pm 0.64
NRCMQS <i>S. aureus</i>	9.50 ^{Cp} \pm 0.11	14.50 ^{Dq} \pm 0.24	17.50 ^{Cr} \pm 0.22	18.50 ^{Cs} \pm 0.21	20.50 ^{Ct} \pm 0.24	30.50 ^{Bu} \pm 0.53

Means bearing different superscripts differ significantly ($p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) within each concentration.

Table 2: Mean \pm S. E. of MIC of different concentrations of MOLAE (hot water) at 1:4 dilution against the selected microorganism

Zone of inhibition (mm)	Concentrations of MOLAE (hot water) -MIC (μ l) for 1:4 dilution					
	Microorganisms	50	100	150	200	250
NCDC 208	2.00 ^{Ap} \pm 0.08	2.00 ^{Ap} \pm 0.07	3.00 ^{Aq} \pm 0.08	3.00 ^{Aq} \pm 0.05	4.00 ^{Ar} \pm 0.07	32.00 ^{Cs} \pm 0.61
NCDC 135	8.00 ^{Cp} \pm 0.07	13.00 ^{Bq} \pm 0.18	17.00 ^{Cr} \pm 0.16	21.00 ^{Ds} \pm 0.24	26.00 ^{Et} \pm 0.36	29.00 ^{Au} \pm 0.77
NCDC133	8.00 ^{Cp} \pm 0.08	10.00 ^{Bq} \pm 0.19	12.00 ^{Br} \pm 0.28	15.00 ^{Bs} \pm 0.16	17.00 ^{Bt} \pm 0.27	32.00 ^{Cu} \pm 0.55
NCDC 138	12.00 ^{Ep} \pm 0.16	16.00 ^{Eq} \pm 0.36	20.00 ^{Er} \pm 0.13	21.00 ^{Ds} \pm 0.29	27.00 ^{Fi} \pm 0.24	31.00 ^{Bu} \pm 0.78
NRCMQS <i>E. coli</i>	4.50 ^{Bp} \pm 0.11	11.00 ^{Cq} \pm 0.13	16.50 ^{Cr} \pm 0.18	18.00 ^{Cs} \pm 0.15	23.00 ^{Dt} \pm 0.31	30.50 ^{Bu} \pm 0.64
NRCMQS <i>S. aureus</i>	9.50 ^{Dp} \pm 0.22	17.50 ^{Fq} \pm 0.34	19.50 ^{Dr} \pm 0.23	20.50 ^{Ds} \pm 0.21	21.50 ^{Ct} \pm 0.31	30.50 ^{Bu} \pm 0.43

Means bearing different superscripts differ significantly ($p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) between columns

b. *Moringa oleifera* seed oil extract

MOSO was extracted using the standard procedure. Methanolic and phenolic extraction was carried out to find out the best way of extraction. The MIC values obtained for phenolic MOSO extract are depicted in Table 3 and for methanolic extract in Table 4.

MIC estimation of MOSO for phenolic extract

The MOSOE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 3). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, different cultures depicted a significant difference in their mean inhibition zone values ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l concentration was observed in NRCMQS *E. coli* (13.00mm), NRCMQS *S. aureus* (19.00mm), NRCMQS *S. aureus* (21.00mm), NRCMQS *S. aureus* (24.00mm), NRCMQS *S. aureus*

(27.00mm), respectively. For NCDC 208, the concentration of 300 μ l revealed the highest mean value of MIC (20.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

MIC estimation of MOSO for methanolic extract

The MOSOE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 4). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, different cultures depicted a significant difference in their mean inhibition zone values ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l concentrations were observed in NRCMQS *S. aureus* with 13.00, 19.00, 21.00, 24.00, and 27.00 mm, respectively. For NCDC 208, the concentration of 300 μ l revealed the highest mean value of the zone of inhibition (26.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

Table 3: Mean \pm S. E. of MIC of different concentrations of *Moringa oleifera* seed oil phenolic extract against the selected microorganism

Zone of inhibition (mm)	Concentrations of MOSO- Phenolic extract- MIC (μ l)					
	Microorganisms	100	150	200	250	300
NCDC 208	9.00 ^{Bp} \pm 0.08	16.00 ^{Dq} \pm 0.17	17.00 ^{Cr} \pm 0.18	19.00 ^{Ds} \pm 0.16	20.00 ^{Bt} \pm 0.27	31.00 ^{Bu} \pm 0.38
NCDC 135	10.00 ^{Cp} \pm 0.07	12.00 ^{Cq} \pm 0.11	13.00 ^{Br} \pm 0.17	17.00 ^{Cs} \pm 0.18	22.00 ^{Dt} \pm 0.26	30.00 ^{Au} \pm 0.57
NCDC133	10.00 ^{Cp} \pm 0.08	11.00 ^{Bq} \pm 0.16	12.00 ^{Ar} \pm 0.18	15.00 ^{As} \pm 0.17	21.00 ^{Ct} \pm 0.28	32.50 ^{Cu} \pm 0.66
NCDC 138	8.00 ^{Ap} \pm 0.14	10.00 ^{Aq} \pm 0.12	13.00 ^{Br} \pm 0.23	16.00 ^{Bs} \pm 0.14	19.00 ^{At} \pm 0.24	30.00 ^{Au} \pm 0.51
NRCMQS <i>E. coli</i>	13.00 ^{Ep} \pm 0.10	16.00 ^{Dq} \pm 0.22	18.00 ^{Dr} \pm 0.31	20.00 ^{Es} \pm 0.24	23.00 ^{Et} \pm 0.33	31.00 ^{Bu} \pm 0.42
NRCMQS <i>S. aureus</i>	11.00 ^{Dp} \pm 0.09	19.00 ^{Eq} \pm 0.18	21.00 ^{Er} \pm 0.19	24.00 ^{Fs} \pm 0.27	27.00 ^{Fi} \pm 0.28	31.00 ^{Bu} \pm 0.59

Means bearing different superscripts differ significantly ($p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) between columns.

Table 4: Mean \pm S. E. of MIC of different concentrations of *Moringa oleifera* seed oil methanolic extract against the selected microorganism

Zone of inhibition (mm)	Concentrations of MOSO- methanolic extract -MIC (μ l)					
	Microorganisms	100	150	200	250	300
NCDC 208	8.00 ^{Ap} \pm 0.08	13.50 ^{Bq} \pm 0.17	14.00 ^{Br} \pm 0.18	18.00 ^{As} \pm 0.16	26.00 ^{Dt} \pm 0.27	31.00 ^{Bu} \pm 0.48
NCDC 135	9.00 ^{Bp} \pm 0.07	16.00 ^{Dq} \pm 0.38	20.00 ^{Er} \pm 0.27	21.00 ^{Cs} \pm 0.38	23.00 ^{Bt} \pm 0.26	30.00 ^{Au} \pm 0.57
NCDC133	8.00 ^{Ap} \pm 0.08	10.00 ^{Aq} \pm 0.06	12.00 ^{Ar} \pm 0.28	20.00 ^{Bs} \pm 0.37	25.00 ^{Ct} \pm 0.38	32.50 ^{Cu} \pm 0.36
NCDC 138	11.00 ^{Cp} \pm 0.14	15.00 ^{Cq} \pm 0.12	17.00 ^{Cr} \pm 0.23	20.00 ^{Bs} \pm 0.32	22.00 ^{At} \pm 0.24	30.00 ^{Au} \pm 0.34
NRCMQS <i>E. coli</i>	11.00 ^{Cp} \pm 0.10	18.00 ^{Eq} \pm 0.16	19.00 ^{Dr} \pm 0.21	23.00 ^{Ds} \pm 0.20	25.00 ^{Ct} \pm 0.33	31.00 ^{Bu} \pm 0.52
NRCMQS <i>S. aureus</i>	13.00 ^{Dp} \pm 0.19	19.00 ^{Fq} \pm 0.28	21.00 ^{Fr} \pm 0.29	24.00 ^{Es} \pm 0.27	27.00 ^{Et} \pm 0.28	31.00 ^{Bu} \pm 0.59

Means bearing different superscripts differ significantly ($p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) between columns.

c. *Moringa oleifera* pod powder aqueous (MOPPA) extract

The MOPPAE was prepared according to the standard procedure. Two sets of dilution, 1:5 and 1:4, of different concentration was used against the selected set of organisms. The MIC values obtained for 1: 5 and 1:4 dilution is depicted in Tables 5 and 6, respectively.

MIC estimation of MOPPA extract for 1:5 dilution

The MOPPAE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 5). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, the different cultures showed a significant difference in their mean values of the zone of inhibition ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l concentration were observed in NCDC 133 (18.00mm), NCDC 135 (20.00mm), NCDC 135 (22.00mm), NRCMQS *S. aureus* (26.00mm) and NRCMQS *S. aureus* (27.00mm), respectively. For NCDC 208, the concentration of 300 μ l

revealed the highest mean value of zone of inhibition (25.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

MIC estimation of MOPA extract for 1:4 dilution

The MOPPAE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 6). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, different cultures depicted a significant difference in their mean inhibition zone values ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l concentrations were observed in NCDC135 (18.00mm), NRCMQS *S. aureus* (20.00mm), NRCMQS *S. aureus* (22.00mm), NRCMQS *S. aureus* (27.00mm), NRCMQS *S. aureus* (28.00mm), respectively. For NCDC 208, the concentration of 300 μ l revealed the highest mean value of zone of inhibition (20.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

Table 5: Mean \pm S. E. of MIC of different concentrations of *Moringa oleifera* pods powder aqueous (MOPPA) extract at 1:5 dilution against the selected microorganism

Zone of inhibition (mm) Microorganisms	Concentrations of MOPPAE- MIC (μ l) for 1:5 dilution					
	100	150	200	250	300	Control
NCDC 208	15.00 ^{Bp} \pm 0.18	19.00 ^{Cq} \pm 0.17	20.00 ^{Br} \pm 0.18	21.00 ^{Cs} \pm 0.26	25.00 ^{Ct} \pm 0.37	32.00 ^u \pm 0.58
NCDC 135	15.00 ^{Bp} \pm 0.17	20.00 ^{Dq} \pm 0.18	22.00 ^{Dr} \pm 0.17	23.00 ^{Es} \pm 0.28	26.00 ^{Dt} \pm 0.21	32.00 ^u \pm 0.67
NCDC133	16.00 ^{Cp} \pm 0.11	17.00 ^{Bq} \pm 0.16	18.00 ^{Ar} \pm 0.18	19.00 ^{As} \pm 0.27	20.00 ^{At} \pm 0.18	32.00 ^u \pm 0.56
NCDC 138	17.00 ^{Dp} \pm 0.14	19.00 ^{Cq} \pm 0.12	21.00 ^{Cr} \pm 0.23	22.00 ^{Ds} \pm 0.34	25.00 ^{Ct} \pm 0.24	32.00 ^u \pm 0.51
NRCMQS <i>E. coli</i>	15.00 ^{Bp} \pm 0.10	17.00 ^{Bq} \pm 0.12	18.00 ^{Ar} \pm 0.21	20.00 ^{Bs} \pm 0.13	21.00 ^{Bt} \pm 0.23	32.00 ^u \pm 0.62
NRCMQS <i>S. aureus</i>	9.00 ^{Ap} \pm 0.09	16.00 ^{Aq} \pm 0.18	18.00 ^{Ar} \pm 0.19	26.00 ^{Es} \pm 0.27	27.00 ^{Et} \pm 0.38	32.00 ^u \pm 0.69

Means bearing different superscripts differ significantly ($P, Q, R, S, T, U, p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) between columns

Table 6: Mean \pm S. E. of MIC (mm) of different concentrations of *Moringa oleifera* pods powder aqueous (MOPPA) extract at 1:4 dilution against the selected microorganism

Zone of inhibition (mm) Microorganisms	Concentrations of MOPPAE- MIC (μ l) for 1:4 dilution					
	100	150	200	250	300	Control
NCDC 208	14.00 ^{Bp} \pm 0.18	15.00 ^{Aq} \pm 0.17	16.00 ^{Ar} \pm 0.18	19.00 ^{As} \pm 0.16	20.00 ^{At} \pm 0.27	32.00 ^u \pm 0.58
NCDC 135	18.00 ^{Fp} \pm 0.17	20.00 ^{Cq} \pm 0.18	21.00 ^{Er} \pm 0.17	25.00 ^{Ds} \pm 0.18	27.00 ^{Dt} \pm 0.16	32.00 ^u \pm 0.67
NCDC133	9.00 ^{Ap} \pm 0.08	15.00 ^{Aq} \pm 0.16	17.00 ^{Br} \pm 0.18	21.00 ^{Bs} \pm 0.27	24.00 ^{Ct} \pm 0.18	32.00 ^u \pm 0.56
NCDC 138	16.00 ^{Dp} \pm 0.14	18.00 ^{Bq} \pm 0.12	20.00 ^{Dr} \pm 0.13	23.00 ^{Cs} \pm 0.24	24.00 ^{Ct} \pm 0.32	32.00 ^u \pm 0.51
NRCMQS <i>E. coli</i>	17.00 ^{Fp} \pm 0.14	18.00 ^{Bq} \pm 0.12	19.00 ^{Cr} \pm 0.11	21.00 ^{Bs} \pm 0.23	22.00 ^{Bt} \pm 0.13	32.00 ^u \pm 0.52
NRCMQS <i>S. aureus</i>	15.00 ^{Cp} \pm 0.19	20.00 ^{Cq} \pm 0.18	22.00 ^{Fr} \pm 0.29	27.00 ^{Es} \pm 0.17	28.00 ^{Et} \pm 0.28	32.00 ^u \pm 0.69

Means bearing different superscripts differ significantly ($P, Q, R, S, T, U, p < 0.05$) between rows and ($A, B, C, D, E, F, p < 0.01$) between columns

d. *Moringa oleifera* gum powder aqueous (MOGPA) extract

The MOGPAE was prepared according to the standard procedure. Two sets of dilution, 1:5 and 1:4, of different concentration was used against the selected set of organisms. The MIC values obtained for 1: 5 dilution and 1:4 dilution is depicted in Table 7 and Table 8, respectively.

MIC estimation of MOGPA extract for 1:5 dilution

The MOGAE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 7). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, the different cultures showed a significant difference in their mean values of the zone of inhibition ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l

concentrations were observed in NCDC 135 (14.00mm), NCDC 135 (16.00mm), NRCMQS *E. coli* (17.00mm), NRCMQS *E. coli* (18.00mm) and NRCMQS *E. coli* (21.00mm), respectively. For NCDC 208, the concentration of 300 μ l revealed the highest mean value of zone of inhibition (10.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

MIC estimation of MOGPA extract for 1:4 dilution

The MOGPAE at different concentrations showed a significant difference ($p < 0.05$), and the mean values of the zone of inhibition increased ($p < 0.05$) as the concentration increased from 100-300 μ l (Table 8). All the values of MIC were significant ($p < 0.05$) in comparison to the control (50 μ l of OTC- antibiotic). Within a concentration, different cultures depicted a significant difference in their mean inhibition zone values ($p < 0.01$). The highest mean values of the zone of inhibition for 100, 150, 200, 250, and 300 μ l concentrations

were observed in NRCMQS *E. coli*, and the values are 16.00, 18.00, 20.00, 22.00, and 24.00mm, respectively. For NCDC 208, the concentration of 300µl revealed the highest mean

value of zone of inhibition (12.00mm). A similar trend was observed for all other NCDC and NRCMQS cultures.

Table 7: Mean ± S. E. of MIC of different concentrations of *Moringa oleifera* gum powder aqueous extract (hot water) at 1:5 dilution against the selected microorganism

Zone of inhibition (mm) Microorganisms	Concentrations of MOGPAE (hot water)- MIC (µl) for 1:5 dilution					
	100	150	200	250	300	Control
NCDC 208	5.00 ^{Bp} ±0.08	6.00 ^{Bq} ±0.07	8.00 ^{Br} ±0.08	9.00 ^{Bs} ±0.06	10.00 ^{Bt} ±0.07	31.00 ^{Bu} ±0.58
NCDC 135	14.00 ^{Fp} ±0.17	16.00 ^{Fq} ±0.18	17.00 ^{Er} ±0.17	18.00 ^{Es} ±0.18	20.00 ^{Et} ±0.16	30.00 ^{Au} ±0.57
NCDC133	8.00 ^{Cp} ±0.08	11.00 ^{Cq} ±0.06	13.00 ^{Cr} ±0.18	14.00 ^{Cs} ±0.17	15.00 ^{Ct} ±0.18	30.00 ^{Au} ±0.56
NCDC 138	12.00 ^{Ep} ±0.14	13.00 ^{Dq} ±0.12	14.00 ^{Dr} ±0.13	15.00 ^{Ds} ±0.14	16.00 ^{Dt} ±0.13	30.00 ^{Au} ±0.51
NRCMQS <i>E. coli</i>	11.00 ^{Dp} ±0.10	14.00 ^{Eq} ±0.12	17.00 ^{Er} ±0.11	18.00 ^{Es} ±0.10	21.00 ^{Et} ±0.13	32.00 ^{Cu} ±0.62
NRCMQS <i>S. aureus</i>	4.00 ^{Ap} ±0.09	5.00 ^{Aq} ±0.08	6.00 ^{Ar} ±0.09	7.00 ^{As} ±0.07	9.00 ^{At} ±0.08	30.00 ^{Au} ±0.59

Means bearing different superscripts differ significantly ($P_{q, r, s, t, u} < 0.05$) between rows and ($A, B, C, D, E, F_p < 0.01$) between columns

Table 8: Mean ± S. E. of MIC of different concentrations of *Moringa oleifera* gum powder aqueous extract (hot water) at 1:4 dilution against the selected microorganism

Zone of inhibition (mm) Microorganisms	Concentrations of MOGPAE (hot water) -MIC (µl) for 1:4 dilution					
	100	150	200	250	300	Control
NCDC 208	7.00 ^{Ap} ±0.08	7.00 ^{Ap} ±0.07	8.00 ^{Aq} ±0.08	10.00 ^{Ar} ±0.06	12.00 ^{As} ±0.17	31.00 ^{Bt} ±0.58
NCDC 135	12.00 ^{Dp} ±0.10	14.00 ^{Dq} ±0.13	15.00 ^{Dr} ±0.12	17.00 ^{Ds} ±0.11	21.00 ^{Et} ±0.16	30.00 ^{Au} ±0.57
NCDC133	10.00 ^{Cp} ±0.08	12.00 ^{Cq} ±0.06	14.00 ^{Cr} ±0.12	16.00 ^{Cs} ±0.14	17.00 ^{Ct} ±0.16	30.00 ^{Au} ±0.66
NCDC 138	13.00 ^{Ep} ±0.14	16.00 ^{Eq} ±0.12	17.00 ^{Er} ±0.13	19.00 ^{Es} ±0.14	20.00 ^{Dr} ±0.16	31.00 ^{Bu} ±0.51
NRCMQS <i>E. coli</i>	16.00 ^{Fp} ±0.11	18.00 ^{Fq} ±0.12	20.00 ^{Fr} ±0.18	22.00 ^{Fs} ±0.20	24.00 ^{Ft} ±0.21	32.00 ^{Cu} ±0.52
NRCMQS <i>S. aureus</i>	8.00 ^{Bp} ±0.09	10.00 ^{Bq} ±0.08	11.00 ^{Br} ±0.09	13.00 ^{Bs} ±0.15	14.00 ^{Bt} ±0.11	30.00 ^{Au} ±0.59

Means bearing different superscripts differ significantly ($P_{q, r, s, t, u} < 0.05$) between rows and ($A, B, C, D, E, F_p < 0.01$) between columns

Discussion

a. MOLAE

For dilution 1:5, the mean values of the zone of inhibition for *Streptococcus agalactiae* were 2 mm in all the concentrations, and for 1:4 dilution, the MIC ranged from 2-4 mm. For different strains of *E. coli*, the mean values of the zone of inhibition ranged from 2-24 mm for 1:5 dilution and 4.5 to 26 mm for 1:4 dilution. Similarly, for the different strains of *Staphylococcus aureus*, the mean values of the zone of inhibition ranged from 2 to 20.50mm for 1:5 dilution and 8 to 21.50mm for 1:4 dilution. The mean values of the zone of inhibition range for *Klebsiella pneumonia* were 2- 23 mm for 1:5 dilution and 12 to 27 mm for 1:4 dilution. The Zone of inhibition reflected for the NRCMQS *S. aureus* culture increased with an increase in concentration compared to NCDC 133 culture, indicating the effectiveness of MOLAE towards the mastitis-causing pathogens in 1:5 dilution. But, a similar pattern of inhibition was not observed with NRCMQS *E. coli* and NCDC135 cultures. Still, at lower concentrations, the NRCMQS *E. coli* showed a comparatively higher zone of inhibition than the NCDC 133 culture in 1:5 dilution. For 1:4 dilution, the NRCMQS cultures depicted the highest zone of inhibition values compared to the NCDC cultures at different concentrations of MOLAE. The present study's findings were in line with Abalaka *et al.* (2012) [1]; Anthonia (2011) [6]; Bukar *et al.* (2010) [10]; Thilza *et al.* (2010) [61]; Nikkon *et al.* (2003) [38]. Ashok and Pari (2003) [8] reported the antibacterial activity of the aqueous extracts of *Moringa oleifera* had inhibition against *S. aureus* (10 mm) and *E. coli* (12 mm), and the values corroborate with the present study. Thus, several studies pointed out that aqueous extract has antibacterial activity against *Escherichia coli* (Anthonia, 2011 [6]; Bukar *et al.*, 2010 [10]; Thilza *et al.*, 2010) [61] with an inhibition zone of 12 mm (Gomashe *et al.*, 2014) [20]; *Staphylococcus aureus* (Nikkon *et al.*, 2003; Vinoth *et al.*, 2012) [38, 62] and other bacterial species (Priya *et al.*, 2011; Abalaka *et al.*, 2012) [47, 1]

which were in line with the present study. Paray *et al.* (2018) [43] reported that the antibacterial activity measured as a zone of inhibition (in mm) for *Moringa oleifera* extract against *E. coli*, *Proteus* spp., *E. faecium*, *E. faecalis*, *S. aureus*, and *S. agalactiae* was 7.50, 12.75, 10.25, 10.25, 8.75, and 8.50, respectively, against bacterial species which were in line with the present study except for the mean values of the zone of inhibition observed for *S. agalactiae*. The variation in the mean values of the zone of inhibition obtained in the present study may be due to the differences in the strains of microorganisms used compared to other studies. The antibacterial activity of the *Moringa oleifera* leaf extract has been studied worldwide. Different concentrations, extraction techniques, and solvents were used to illustrate the potency of the extracts obtained in each case. Pandit and Vyas (2020) [42] conducted a study to identify the antibacterial activity of *M. oleifera* aqueous leaf extract. The leaf extract showed the most potent antibacterial activity against *P. aeruginosa* (20 mm) at its highest 200 mg/ml concentration. In addition, *M. oleifera* leaf extract showed an intermediate antibacterial effect against *S. aureus*, Coagulase-negative *Staphylococci*, *Enterobacter* spp., and *Streptococcus* spp. A similar study was conducted by Akpor *et al.* (2020) [4] to evaluate the antibacterial activity of ethanolic leaf extracts of *Moringa oleifera* and found that extracts inhibit the growth of *Escherichia coli*, *Staphylococcus aureus* (MIC- 500 mg/L), *Pseudomonas aeruginosa* (MIC- 1000 mg/L), and *Bacillus subtilis* (MIC- 500 mg/L). The phytochemical constituents in the ethanolic extract include alkaloids, cardiac glycosides, terpenoids, tannins, saponins, and phlorotannins. *Klebsiella* spp. was inhibited in all the concentrations of *Moringa* ethanolic extract in the study. On the other hand, Singh and Tafida (2013) [59] reported that the aqueous, ethanol, and methanol extracts of the moringa leaves have an inhibitory ability against *Escherichia coli*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*. They also pointed out that the

inhibitory effects of the extracts were significantly higher on *Escherichia coli* than on *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Kalpana *et al.* (2013) [28] reported that Moringas' petroleum ether, ethanol, aqueous, and chloroform extracts had maximum antibacterial activity against *Staphylococcus aureus*. Ajayi and Fadeyi (2015) [3] observed that petroleum ether extract of Moringa leaf has more inhibitory activity against *Streptococcus* spp. than *Staphylococcus aureus*. Thus, the present study aligned with the above findings about the antimicrobial activity of moringa leaf extract.

b. MOSO

In the current study, the phenolic extract exhibited mean values of the zone of inhibition of 9 to 20 mm, and for methanolic extract, it was 8 to 26 mm for *Streptococcus agalactiae*. The mean values of the zone of inhibition ranged from 10 to 23 mm for phenolic extract and 9 to 25 mm for methanolic extract for *E. coli* strains used in the present study. The mean values of the zone of inhibition ranged between 10-27 mm for a phenolic extract and 8-27 mm for a methanolic extract for various concentrations used against *S. aureus*. For *Klebsiella pneumoniae*, the mean values of the zone of inhibition ranged from 8 to 19 mm and 11 to 22 mm for phenolic and methanolic extract, respectively. The mean values of the zone of inhibition of antibiotic solution against the different strains of microorganisms used in the present study were the highest and ranged from 30 to 32.50 mm. For phenolic and methanolic extracts, the NRCMQS cultures depicted the highest zone of inhibition values compared to the NCDC cultures at different concentrations of MOSO. Several studies have reported the antibacterial activity of MOSO (Ramachandran *et al.*, 1980; Chuang *et al.*, 2007; Salaheldeen *et al.*, 2014) [50, 12, 55]. Amina *et al.* (2019) [5] determined the MIC of MOSO against strains of *Staphylococcus aureus*, *E. coli*, *Klebsiella pneumoniae*, *Salmonella typhi*, *Pseudomonas aeruginosa*, *Shigella flexneri*, and *Candida albicans* at 50 mg mL⁻¹ concentrations 8, 5, 10, 8, 4, 7, 12 mm, respectively. The inhibition zone against bacteria ranges from 10-16 mm at 50 mg mL⁻¹ concentration. The observations of the present study were higher than the reported as the concentration of MOSO used was from 100-300 µl. Similarly, Farhan *et al.* (2021) [16] reported the antibacterial effect of MOSO against *Staphylococcus aureus*, *Escherichia coli*, *Bacillus cereus*, and *Klebsiella pneumoniae* in all concentrations tested except for *E. coli* and *K. pneumoniae*, which at a concentration of 125 µl/ml in petroleum ether solvent extraction of oil. The MIC and inhibition zone for *Staphylococcus aureus*, *Bacillus cereus*, *E. coli*, and *Klebsiella pneumoniae* were 64, 128, 256, 256 µl/ml and 18.50, 14.16, 11.83, and 11.33 mm in concentration 500 µl/ml, respectively, which were in line with the present study even though the extraction procedure of oil was different. Moringa seed oil, a light-coloured yellow oil, has excellent properties as an emollient along with *Aloe vera* and *Curcuma caesia* extracts. The said oil is equivalent to olive oil in its benefits. In addition, Moringa oil contains 6-10% behenic acid, which provides a unique skin feel and is attributed to the oxidative stability of the oil. Similarly, Aloe Vera is an excellent moisturizer used commercially in the cosmetic industry (Nandagopal *et al.*, 2011) [37]. Pharmacological investigations have proved that the *Moringa oleifera* seed oil (MOSO) has several biological activities, including antioxidant, anticancer,

antibacterial, antifertility, antifungal (Ramachandran *et al.*, 1980; Chuang *et al.*, 2007) [50, 12], skin protecting effect, anti-rheumatic and anti-hypertensive properties (Mahmood *et al.*, 2010) [34]. These findings were in line with the present study as the colour of the moringa oil isolated was light-yellow and manifested several properties in due course of the experiment.

c. MOPPAE

M. oleifera pods powder (MOPP) has an array of antimicrobial activities (Sayeed *et al.*, 2012) [56], are a good source of saponins, the plant glycosides with triterpene or steroid aglycone (Paliwal *et al.*, 2011) [40]. The mean values of inhibitory zones ranged between 15 to 25 mm against *Streptococcus agalactiae*, 15 to 26 mm against different strains of *E. coli*, 9 to 27 mm against different strains of *Staphylococcus aureus*, 17 to 25 mm against *Klebsiella pneumoniae* for the different concentrations of 1:5 dilution in the present study. Similarly, the mean values of inhibitory zones ranged between 14 to 20 mm against *Streptococcus agalactiae*, 18 to 27 mm against different strains of *E. coli*, 9 to 28 mm against different strains of *Staphylococcus aureus*, 16 to 24 mm against *Klebsiella pneumoniae* for the different concentrations of 1:4 dilution. For 1:5 dilution, the NCDC cultures depicted the highest zone of inhibition values compared to the NRCMQS cultures at different concentrations of MOPPAE, except for the NRCMQS *S. aureus* at 250 and 300 µl of MOPPAE. For 1:4 dilution, the NRCMQS *S. aureus* depicted the highest zone of inhibition values compared to the NCDC 133 at different concentrations of MOPPAE, and a reverse pattern is observed with NRCMQS *E. coli* and NCDC 133. Kheir *et al.* (2014) [30] reported MOPP alcoholic extract showed antibacterial activity against all the tested gram-positive bacteria. MOPP alcoholic extract showed a maximum inhibition zone of 28 mm at 500 mg/ml concentration for *S. aureus*. The aqueous extracts also showed antibacterial activity against gram-positive bacteria. Jabeen *et al.* (2008) [27] observed that the crude extracts of MOPP exhibited zone inhibition of 21, 31, 36, and 20 mm against *Pasturella multocida*, *Staphylococcus aureus*, *Bacillus subtilis*, and *Escherichia coli*, which was in line with the present study. Several studies reported the antimicrobial activity of moringa pods (Suganandam *et al.*, 2022 [60]; Premi and Sharma, 2017 [46]; Govardhan *et al.*, 2013 [21]; Karmakar *et al.*, 2010) [29] that are in agreement with the present study.

d. MOGPAE

Panda (2014) reported that Moringa gum is hydrophilic, and the emulsion created is stable compared to acacia gum. The emulsion of moringa gum is least affected by centrifugation, pH, temperature changes, and electrolytes. Moringa gum is a non-adhesive mucopolymer (Singh and Kumar, 2018) [58] (Rimpy *et al.*, 2017) [51]. Thus, it can be used as an agent of thickening, stabilizing, and gelling (Kumar and Renuka, 2019) [33]. The MIC of MOGPAE was carried out at 1:5 and 1:4 dilutions for different concentrations against the selected microorganism in the present study. The mean values of inhibitory zones ranged between 5 to 10 mm against *Streptococcus agalactiae*, 11 to 21 mm against different strains of *E. coli*, 4 to 15 mm against different strains of *Staphylococcus aureus*, 12 to 16 mm against *Klebsiella pneumoniae* for the different concentrations of 1:5 dilution. Similarly, the mean values of inhibitory zones ranged between 7 to 12 mm against *Streptococcus agalactiae*, 12 to

24 mm against different strains of *E. coli*, 8 to 17 mm against different strains of *Staphylococcus aureus*, 13 to 20 mm against *Klebsiella pneumoniae* for the different concentrations of 1:4 dilution. The mean values of the zone of inhibition observed for the antibiotic solution used against the selected microorganisms ranged between 30 to 32 mm for the present study. For both dilutions, the NRCMQS *S. aureus* depicted the highest zone of inhibition values compared to the NCDC 133 at different concentrations of MOGPAE. For 1:4 dilution, the NRCMQS *E. coli* showed the highest zone of inhibition values compared to the NCDC 135 to varying concentrations of MOGPAE. Still, for 1: 5 dilutions, a reverse trend was observed except for the concentration of 300µl MOGPAE. Irfan *et al.* (2021) [26] conducted an experiment and successfully synthesized zinc oxide and silver nitrate nanoparticles (NPs), where Moringa gum was the reducing and capping agent. They further analyzed their antimicrobial activity against MRSA, *E. coli*, and *S. aureus*. The concentration of gum was 50 per cent in NPs. The zone of exhibition exhibited by NPs of AgNPs and ZnO against *E. coli*, *S. aureus*, and MRSA were 21 and 22, 20 and 21, and 16 and 17 mm, respectively. The validation of the present test needs additional citations as similar studies about the mean values obtained for MOGPAE against the selected microorganisms are lacking.

The nature and amount of active ingredients present in the various extracts of Moringa depend on the method and the extraction solvent (Vongsak *et al.*, 2013) [63]. Not only the technique of extraction but also the geographical location, climatic variations, soil, and intensity of the solar radiation received (Wink, 2003) [65] affect the quality of active compounds present in Moringa. Several studies reported various bioactive compounds and secondary metabolites such as quercetin, gallic acid, chlorogenic acid, glucosinolates, ferulic acid, phenolic acids, vanillin, kaempferol, ellagic acid, and flavonoids (Coppina *et al.*, 2013) [13] in moringa flowers, seeds, leaves, pods, stem and bark (Mbikay, 2012) [35]. The major antibacterial compounds isolated from *M. oleifera* (Thilza *et al.*, 2010) [61] include isothiocyanates (4-(4'-O-acetyl-a-L rhamnopyranosyloxy) benzyl isothiocyanate, 4-(a-L-rhamnopyranosyloxy) benzyl isothiocyanate, benzyl isothiocyanate, pterygospermin, niazimicin, 4-(a-L-rhamnopyranosyloxy) benzyl glucosinolate), pterygospermin, glucosinolates and rhamnose (Fuglie, 2000) [18]. Thus, the antibacterial activity manifested by the various extracts of Moringa in the present study is due to the bioactive compounds and secondary metabolites. The degree of antimicrobial activity exhibited by the various dilutions used in the current study is due to the variations in the amount of bioactive compounds in the respective extracts.

Conclusion

The different bacterial cultures of NCDC and NRCMQS showed a significant increase in the mean values of the zone of inhibition of different concentrations of MOLAE, MOSO, MOPPAE, and MOGPAE to the control group ($p < 0.05$), and the different cultures differ significantly ($p < 0.01$) within the MIC each extract. Mastitic cultures showed the highest zone of inhibition with the different Moringa extracts, indicating the aqueous extract's effectiveness over NCDC cultures. Thus, Moringa could be utilized in developing prophylactic solutions against mastitis.

Acknowledgment

The authors are grateful to the Director, ICAR- National Dairy Research Institute (NDRI), for providing all the necessary facilities and funds to conduct the study. Also, to the in-charges of NRCMQS and NCDC for providing all the cultures necessary to conduct the study.

References

1. Abalaka ME, Daniyan SY, Oyeleke SB, Adeyemo SO. The antibacterial evaluation of *Moringa oleifera* leaf extracts on selected bacterial pathogens. *Journal of Microbiology Research*. 2012;2(2):1-4.
2. Abraham NA, Okon GO. Antibacterial effect of *Moringa oleifera* extracts on bacteria associated with urinary tract infection. *International Journal of Research*, 2014;1(8):1308-1316.
3. Ajayi AO, Fadeyi TE. Antimicrobial activities and phytochemical analysis of *Moringa oleifera* leaves on *Staphylococcus aureus* and *Streptococcus* species. *American Journal of Phytomedicine and Clinical Therapeutics*. 2015;3(10):643-653.
4. Akpor OB, Hussein FU, Olaolu TD, Alabi OO. Antibacterial potential of ethanol leaves extracts of *Helianthus annuus*, *Moringa oleifera*, *Euphorbia heterophylla*, and *Physalis angulata*. *Asian Journal of Agriculture and Biology*. 2020;8(3):330-340.
5. Amina M, Al-Musayeib NM, Alarfaj NA, El-Tohamy MF, Orabi HE, Bukhari SI, et al. Exploiting the potential of *Moringa oleifera* oil/polyvinyl chloride polymeric bio-nanocomposite film enriched with silver nanoparticles for antimicrobial activity. *International Journal of Polymer Science*. 2019;2019:1-11.
6. Anthonia OO. Evaluation of antimicrobial properties and nutritional potentials of *Moringa oleifera* Lam. leaf in South-Western Nigeria. *Malaysian Journal of Microbiology*. 2011;8(2):59-67.
7. Anwar F, Latif S, Ashraf M, Gilani AH. *Moringa oleifera*: a food plant with multiple medicinal uses. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2007;21(1):17-25.
8. Ashok KN, Pari L. The antioxidant action of *Moringa oleifera* Lam. (drumstick) against anti-tubercular drug induced lipid peroxidation in rats. *Journal of Medicinal Food*. 2003;6(3):255-259.
9. Awale MM, Dudhatra GB, Avinash K, Chauhan BN, Kamani DR, Modi CM, et al. Bovine mastitis: a threat to the economy. *Scientific Reports*. 2012;1:295-305.
10. Bukar A, Uba A, Oyeyi T. Antimicrobial profile of *Moringa oleifera* Lam. extract against some food-borne microorganisms. *Bayero Journal of Pure and Applied Sciences*. 2010;3(1):43-48.
11. Calvino LF, Tirante L. Prevalencia de microorganismos patógenos de mastitis bovina y evolución del estado de salud de la glándula mamaria en Argentina en los últimos 25 años. *Revista FAVE*. 2005;4(1-2):29-40.
12. Chuang PH, Lee CW, Chou JY, Murugan M, Shieh BJ, Chen HM. Antifungal activity of crude extracts and essential oil of *Moringa oleifera* Lam. *Bioresource Technology*. 2007;98:232-236.
13. Coppina JP, Xua Y, Chena H, Panb M, Hoc C, Juliania R, et al. Determination of flavonoids by LC/MS and anti-inflammatory activity in *Moringa oleifera*. *Journal of*

- Functional Foods. 2013;5:1892-1899.
14. Daba M. Miracle tree: A review on multi-purposes of *Moringa oleifera* and its implication for climate change mitigation. *Journal of Earth Science and Climatic Change*. 2016;7(8):8-24.
 15. Elgamily H, Moussa A, Elboraey A, EL-Sayed H, Al-Moghazy M, Abdalla A. Microbiological assessment of *Moringa oleifera* extracts and its incorporation in novel dental remedies against some oral pathogens. *Open Access Macedonian Journal of medical sciences*. 2016;4(4):585-590.
 16. Farhan DR, AL-Azawi AH, Salih WY, Abdulhassan AA. The antibacterial and antioxidant activity of *Moringa Oleifera* seed oil extract against some food-borne pathogens. *Indian Journal of Forensic Medicine and Toxicology*. 2021;15(4):2529-2539.
 17. Fuglie LJ. The miracle tree: *Moringa oleifera*: Natural Nutrition for the Tropics, Church World Service, Dakar, Published as The Miracle Tree: The Multiple Attributes of Moringa, 1999, p. 172-184.
 18. Fuglie LJ. New Uses of Moringa Studied in Nicaragua: ECHO's Technical Network Site-networking global hunger solutions. ECHO, Nicaragua, 2000.
 19. Golla K, Vutukuru S, Rani J, Meghanath P, Pasha C. Screening of small peptides from various germinating seeds having antimicrobial activity. *Journal of Pharmaceutical and Biomedical Analysis*. 2006;11:2278-3008.
 20. Gomashe AV, Gulhane PA, Junghare MP Dhakate NA. Antimicrobial activity of Indian medicinal plants: *Moringa oleifera* and *Saraca indica*. *International Journal of Current Microbiology and Applied Sciences*. 2014;6(3):161-169.
 21. Govardhan SRS, Negi PS, Radha C. Phenolic composition, antioxidant and antimicrobial activities of free and bound phenolic extracts of *Moringa oleifera* seed flour. *Journal of Functional Foods*. 2013;5:1883-1891.
 22. Grubben G, Denton O. *Plant Resources of Tropical Africa*, Earth prints limited. Stevenage, UK, 2004, p. 56-60.
 23. Gull I, Javed A, Aslam MS, Mushtaq R, Athar AM. Use of *Moringa oleifera* flower pod extract as a natural preservative and development of SCAR marker for its DNA-based identification. *BioMed Research International*. 2016;2016:1-12.
 24. Haldar R, Kosankar S. *Moringa Oleifera*: The Miracle Tree. *International Journal of Advance Research, Ideas and Innovations in Technology*. 2017;3(6):966-970.
 25. Ighodaro OM, Akinloye OA. First-line defence antioxidants-superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX): they're a fundamental role in the entire antioxidant defence grid. *Alexandria Journal of Medicine*. 2018;54(4):287-293.
 26. Irfan M, Munir H, Ismail H. *Moringa oleifera* gum-based silver and zinc oxide nanoparticles: green synthesis, characterization and their antibacterial potential against MRSA. *Biomaterials Research*. 2021;25:17-29.
 27. Jabeen, R, Shahid M, Jamil A, Ashraf M. Microscopic evaluation of the antimicrobial activity of seed extracts of *Moringa oleifera*. *Pakistan Journal of Botany*. 2008;40(4):1349-1358.
 28. Kalpana S, Morthi S, Kumari S. Antimicrobial activity of different extracts of leaf of *Moringa oleifera* (Lam.) against Gram-positive and Gram-negative bacteria. *International Journal of Current Microbiology and Applied Sciences*. 2013;2:514-518.
 29. Karmakar A, Karmakar S, Mukherjee S. Properties of various plants and animal feedstocks for biodiesel production. *Bioresource Technology*. 2010;101:7201-7210.
 30. Kheir SM, Kafi SK, Elbir H. The antimicrobial activity and phytochemical characteristics of *Moringa oleifera* seeds, leaves, and flowers. *World Journal of Pharmaceutical Research*, 2014;4(1):258-272.
 31. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. *Drugs*. 2003;63(4):389-406.
 32. Krishnamoorthy P, Suresh KP, Saha S, Govindaraj G, Shome BR, Parimal R. Meta-analysis of the prevalence of subclinical and clinical mastitis, major mastitis pathogens in dairy cattle in India. *International Journal of Current Microbiology and Applied Sciences*. 2017;6(3):1214-1234.
 33. Kumar RS, Renuka R. Isolation and characterization of *Moringa oleifera* Gum: A novel sustained release polymer. *Journal of Drug Delivery and Therapeutics*. 2019;9:484-486.
 34. Mahmood M, Mugal T, Haq IU. *Moringa oleifera*: a natural gift- a review. *Journal of Pharmaceutical Sciences and Research*. 2010;2:775-781.
 35. Mbikay M. Therapeutic potential of *Moringa oleifera* leaves in chronic hyperglycemia and dyslipidemia: a review. *Frontiers in Pharmacology*. 2012;3:24-32.
 36. Mir AQ, Bansal BK, Gupta DK. Subclinical mastitis in machine milked dairy farms in Punjab: prevalence, distribution of bacteria and current antibiogram. *Veterinary World*, 2014;7(5):291-294.
 37. Nandagopal B, Sankar S, Ramamurthy M, Sathish S, Sridharan G. Could the products of Indian medicinal plants be the next alternative for the treatment of infections? *Indian Journal of Medical Microbiology*, 2011;29:93-101.
 38. Nikkon F, Saud ZA, Rahman MH, Haque ME. In vitro antimicrobial activity of the compound isolated from chloroform extract of *Moringa oleifera* Lam. *Pakistan Journal of Biological Sciences*. 2003;6(22):1888-1890.
 39. Onsare J, Kaur H, Arora D. Antimicrobial activity of *Moringa oleifera* from different locations against some human pathogens. *Academia Journal of Medicinal Plants*. 2013;1(5):080-091.
 40. Paliwal R, Sharma V, Pracheta. A review on horse radish tree (*Moringa oleifera*): A multipurpose tree with high economic and commercial importance. *Asian Journal of Biotechnology*. 2011;3(4):317-328.
 41. Panda D, Si S, Swain S, Kanungo SK, Gupta R. Preparation and evaluation of gels from the gum of *Moringa oleifera*. *Indian Journal of Pharmaceutical Sciences*. 2006;68:777-80.
 42. Pandit BR, Vyas A. Efficacy of antibacterial action on seven medicinal plant extracts against neonatal sepsis causing bacteria-an in vitro study. *Plant Archives*. 2020;20(2):2487-2494.
 43. Paray RA, Bhakat M, Mohanty TK, Behare P, Lone SA, Parry UR, et al. Antimicrobial activity of crude aqueous extracts of *Moringa oleifera*, *Azadirachta indica*,

- Caricapapaya*, *Tinospora cordifolia* and *Curcuma longa* against certain bacterial pathogens. Journal of Pharmacognosy and Phytochemistry. 2018;7(4):984-994.
44. Pilipčincová I, Bhide M, Dudříková E, Trávníček M. Genotypic characterization of coagulase-negative *Staphylococci* isolated from sheep milk in Slovakia. Acta Veterinaria Brunensis. 2010;79:269-275.
 45. Pitkala A, Haveri M, Pyorala S, Myllys V, Honkanen-Buzalski T. Bovine mastitis in Finland 2001- Prevalence, distribution of bacteria, and antimicrobial resistance. Journal of Dairy Science. 2004;87:2433-2441.
 46. Premi M, Sharma HK. Effect of extraction conditions on the bioactive compounds from *Moringa oleifera* (PKM 1) seeds and their identification using LC-MS. Food Measure. 2017;11:213-225.
 47. Priya VP, Abiramasundari S, Gayathri D, Jayanthi GP. Antibacterial activity of the leaves, bark, seed, and flesh of *Moringa Oleifera*. Pakistan Journal of Pharmaceutical Sciences. 2011;2(8):2045-2049.
 48. Radostits OM, Leslie KE, Fetrow J. Mastitis control in dairy herds. Herd Health Food Animal Production Medicine, 2nd ed. W. B. Saunders, Philadelphia, 1994, p. 229-273.
 49. Raj AJ, Gopalakrishnan VK, Yadav SA, Dorairaj S. Antimicrobial activity of *Moringa oleifera* (Lam.) root extract. Journal of Pharmacy Research. 2011;4(5):1426-1427.
 50. Ramachandran C, Peter KV, Gopalakrishnan PK. Drumstick (*Moringa oleifera*): a multipurpose Indian vegetable, Economic Botany. 1980;34(3):276-283.
 51. Rimpay, Abhishek, Ahuja M. Evaluation of carboxymethyl moringa gum as a nanometric carrier. Carbohydrate Polymers. 2017;174:896-903.
 52. Saad NKM. Comparison of *Moringa olieifera* seed oil characterization produced by chemical and mechanical methods. Thesis submitted to Faculty of Chemical and Natural Resources Engineering, University of Malaysia, Pahang, 2015.
 53. Saini DK, Saini MR. Evaluation of radioprotective efficacy and possible mechanism of action of *Aloe* gel. Environmental Toxicology and Pharmacology. 2011;31:427-435
 54. Sakwinska O, Giddey M, Moreillon M, Morisset D, Waldvogel, Moreillon P. *Staphylococcus aureus* host range and human-bovine host shift. Applied and Environmental Microbiology. 2011;77(17):5908-5915.
 55. Salaheldeen M, Arouaa MK, Mariod AA, Chenge SF, Abdelrahmanb AM. An evaluation of *Moringa peregrina* seeds as a source for biofuel. Industrial Crops and Products. 2014;61:49-61.
 56. Sayeed MA, Hossain MS, Chowdhury MEH, Haque M. *In vitro* antimicrobial activity of methanolic extract of *Moringa oleifera* Lam. fruits. Journal of Pharmacognosy and Phytochemistry. 2012;1(4):94-98.
 57. Sharma N, Maiti SK. Incidence, etiology, and antibiogram of subclinical mastitis in cows in Durg, Chhattisgarh. Indian Journal of Veterinary Research. 2010;19:45-54.
 58. Singh B, Kumar A. Network formation of *Moringa oleifera* gum by radiation-induced crosslinking: Evaluation of drug delivery, network parameters and biomedical properties. International Journal of Biological Macromolecules. 2018;108:477-488.
 59. Singh K, Tafida GM. Antibacterial activity of *Moringa oleifera* (Lam) leaves extract against some selected bacteria. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;6(9):52-54.
 60. Sukanandam K, Jeevalatha A, Kandeepan C, Kavitha N, Senthilkumar N, Sutha S, *et al.* Profile of phytochemicals and GCMS analysis of bioactive compounds in natural dried-seed removed ripened pods methanolic extracts of *Moringa oleifera*. Journal of Drug Delivery and Therapeutics. 2022;12(5-S):133-141.
 61. Thilza IB, Sanni S, Sanni ZA, Muhammed FS, Talle, Musa BJ. *In-vitro* antimicrobial activity of water extract of *Moringa oleifera* leaf stalk on bacteria normally implicated in eye diseases. Nigeria Academia Arena, 2010;2(6):80-82.
 62. Vinoth B, Manivasagaperumal R, Balamurugan S. Phytochemical analysis and antibacterial activity of *Moringa oleifera* lam, India. International Journal of Research in Biological Sciences. 2012;2(3):98-102.
 63. Vongsak B, Sithisarn P, Mangmool S, Thongpraditchote S, Wongkrajang Y, Gritsanapan W. Maximizing total phenolics, total flavonoid contents and antioxidant activity of *Moringa oleifera* leaf extract by the appropriate extraction method. Industrial Crops and Products. 2013;44:566-571.
 64. Wang XM, Zhang WJ, Schwarz S, Yu SY, Liu H, Si W. Methicillin-resistant *Staphylococcus aureus* ST9 from a case of bovine mastitis carries the genes *cf*r and *erm* (A) on a small plasmid. Journal of Antimicrobial Chemotherapy. 2012;67:1287-1289.
 65. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry, 2003;64(1):3-19.
 66. Zadoks R, Fitzpatrick J. Changing trends in mastitis. Irish Veterinary Journal. 2009;62(4):59-70.
 67. Zadoks RN, Middleton JR, McDougall S, Katholm J, Schukken YH. Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans. Journal of Mammary Gland Biology and Neoplasia. 2011;16(4):357-72.
 68. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.